Recombinant Anti-CD55 x Anti-HLA-A Bispecific Antibody (scIgG) is designed to be expressed as two chains, each chain has the same units with their parental IgG antibodies, anti-CD55 and anti-HLA-A IgGs. The two chains form heterodimer via Fc KIH technology. This BsAb can recruit complements to tumor cells. It is designed for the research of Renal cell cancer (RCC); Solid tumors therapy.
Welcome! For price inquiries, we will get back to you as soon as possible.
INQUIRY